4Tefferi A,Pardanani A,Lim KH,et al.TET2 mutations and their clinical correlates in polycythemia vera,essential thrombocythemia and myelofibrosis[J].Leukemia,2009,23:905-911. 被引量：1
5Schnittger S,Meggendorfer M,Kohlmann A,et al.SRSF2is mutated in 47.2%(77/163)of chronic myelomonocytic leukemia(CMML)and prognostically favorable in case with concomitant RUNX1mutations[J].Blood,2011,118:274. 被引量：1
6Abdel-Wahab O,Pardanani A,Patel J,et al.Concomitant analysis of EZH2and ASXL1 mutations in myelofibrosis,chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasma[J].Leukemia,2011,25:1200-1202. 被引量：1
7Bejar R,Stevenson K,Abdel-Wahab O,et al.Clinical effect of point mutations in myelodysplastic syndromes[J].N Engl J Med,2011,364:2496-2506. 被引量：1
8Abdel-Wahab O,Manshouri T,Patel J,et al.Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias[J].Cancer Res,2010,70:447-452. 被引量：1
9Tefferi A,Jimma T,Sulai NH,et al.IDH mutations in primary myelofibrosis predict leukemic transformation and shortened suvival:clinical evidence for leukemogenic collaboration with JAK2V617F[J].Leukemia,2012,26:475-480. 被引量：1
10Tefferi A,Lasho TL,Abdel-Wahab O,et al.IDH1and IDH2mutation studies in 1473patients with chronic-,fibrotic-or blast-phase essential throbcythemia,polycythemia vera or myelofibrosis[J].Leukemia,2010,24:1302-1309. 被引量：1
